NORTH CHICAGO, Ill. | July 1, 2026
Rosalind Franklin University of Medicine and Science (RFU) has showcased groundbreaking advances in reproductive immunology at the 2026 American Society for Reproductive Immunology (ASRI) Annual Meeting, reinforcing its position as a global leader in infertility research. Ranked as the world’s No. 1 Reproductive Immunology Program by ScholarGPS, RFU presented a series of innovative studies focused on uncovering the immune mechanisms underlying infertility, recurrent pregnancy loss, implantation failure, and diminished ovarian reserve. The presentations highlighted emerging immunotherapy strategies, novel biomarkers, and immune-endocrine interactions that could transform reproductive medicine and improve pregnancy outcomes for women affected by immune-mediated infertility. Led by internationally recognized reproductive immunologist Dr. Joanne Kwak-Kim, the research reflects growing scientific interest in understanding how immune dysfunction contributes to infertility and pregnancy complications. With infertility rates continuing to rise globally, the findings presented at ASRI provide valuable insights that may guide the development of precision reproductive medicine and future therapeutic approaches for couples struggling to conceive.
Innovative Reproductive Immunology Research Highlights New Therapeutic Opportunities
At the ASRI Annual Meeting, Dr. Joanne Kwak-Kim, Director of Reproductive Medicine and Immunology at RFU, chaired the scientific session “Breaking Barriers: Innovative Immunotherapies in Human Reproduction,” bringing together leading experts investigating immune-targeted approaches to infertility. The RFU research team presented multiple studies examining how immune system dysregulation influences reproductive success and pregnancy outcomes.
Topics included the endometrial immune environment, the impact of sex steroid hormones on cytokine production, and the effectiveness of immunotherapy in women with recurrent pregnancy loss and diminished ovarian reserve. These investigations demonstrate how immune profiling may help identify patients most likely to benefit from personalized treatment strategies while improving understanding of the biological mechanisms driving infertility.
Studies Reveal New Biomarkers for Infertility and Pregnancy Loss
Advertisement
RFU researchers also presented several important scientific posters exploring novel immune biomarkers associated with reproductive disorders. Investigations examined the role of Anti-Müllerian Hormone (AMH) as a direct regulator of immune signaling, interactions between the IGF/IGFBP pathway and natural killer (NK) cell activity, and the influence of autoimmune responses on ovarian reserve in women experiencing recurrent reproductive failure.
Additional research evaluated immune plasticity by studying proteins involved in inflammatory regulation that may contribute to implantation failure and unsuccessful pregnancies. Together, these findings provide deeper insight into the complex relationship between the immune, endocrine, and metabolic systems, supporting the development of more targeted diagnostic tools and individualized therapeutic interventions for infertility patients.
Advancing Precision Medicine in Women’s Reproductive Health
The scientific presentations further strengthen Rosalind Franklin University’s reputation as a leader in reproductive immunology, a rapidly expanding field with significant implications for women’s health and precision medicine. Infertility affects millions of individuals worldwide, while declining fertility rates continue to pose growing public health challenges. By identifying immune-mediated causes of infertility and exploring innovative immunotherapeutic approaches, RFU researchers are helping advance more personalized treatment strategies capable of improving pregnancy success rates and reducing recurrent pregnancy loss.
The university’s multidisciplinary research program integrates expertise in clinical immunology, reproductive medicine, endocrinology, and translational science, creating opportunities to develop next-generation diagnostics and therapies for patients with complex reproductive disorders. As reproductive immunology continues to evolve, the studies presented at the ASRI Annual Meeting highlight the increasing importance of immune-targeted precision medicine in addressing infertility and expanding treatment options for patients worldwide.
Source: Rosalind Franklin University press release
